Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on Oncology and Lung cancer, with related work in Digital polymerase chain reaction, T790M, Irinotecan. Notable publications include 'Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays “cold” immune characteristics in Non-small cell lung cancer', 'Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients', and 'Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC'.
Efficacy and safety of tislelizumab plus anlotinib and irinotecan as second-line treatment for extensive-stage small cell lung cancer: a single-arm, open-label, phase II trial
Efficacy and Safety of Tislelizumab Plus Anlotinib and Irinotecan as Second-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single-Arm, Open-Label, Phase II Trial
PD-1 Combined with VEGF/VEGFR2 Inhibitors for the Re-Treatment of Metastatic Nasopharyngeal Carcinoma
Prognostic and Metabolic Characteristics of a Novel Cuproptosis Related Signature in Hepatocellular Carcinoma Patients
Identification of Immune-related Cuproptosis Genes in the Prognosis of Thyroid Cancer
Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays “cold” immune characteristics in Non-small cell lung cancer
A phaseⅠ/Ⅱa clinical study of cetuximab combined with fruquintinib in the third-line treatment of RAS/BRAF wild-type colorectal cancer.
Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non–small-cell Lung Cancer
Which Acts Better in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, Specific Gene Co-Variation or Number of Concomitant Mutated Genes?
Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients
Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC
Estimation of cell-free circulating <i>EGFR</i> mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer